I would only add that I think fewer than a hundred girls in the 12- to 13-year-old age category were actually subjected to clinical trials.
There have been some assumptions made in the clinical testing: first of all, that younger girls would be similar to older girls and young women; and secondly, that it was important they vaccinate girls who had not yet become sexually active because their risk of having been infected already with HPV was so high, and that would have rendered the vaccine absolutely useless. So it was important to demonstrate efficacy by testing it on girls who were not yet exposed.
The other thing is that the groups that are most at risk tend to be immigrants, Innu women, and people in remote locations. Apparently, at least for some subpopulations, the virus causing HPV among some of those populations is not the one targeted by Gardasil, so we have a problem there as well.
I think this program was just launched a little too hastily.